## **Listing of Claims**:

1. (Previously presented) A method for reversing drug resistance in a cancer cell, said method comprising introducing an antisense glucosylceramide synthase nucleic acid sequence into said cell, wherein said introduction reverses drug resistance in said cell.

## 2. (Canceled)

- 3. (Previously presented) The method of claim1, wherein said nucleic acid sequence is complementary to all or part of a sense strand for glucosylceramide synthase.
- 4. (Original) The method of claim 3, wherein said nucleic acid sequence is between about 15 to about 25 nucleotides in length.
- 5. (Original) The method of claim 1 wherein said cancer cell is selected from the group consisting of a breast cancer cell, prostate cancer cell, ovarian cancer cell, lymphoma cell, melanoma cell, sarcoma cell, leukemia cell, retinoblastoma cell, hepatoma cell, myeloma cell, glioma cell, mesothelioma cell or carcinoma cell.
- 6. (Original) The method of claim 1, further comprising the step of contacting said cell with at least one other agent.
- 7. (Original) The method of claim 6 wherein said agent is a chemosensitizer or chemotherapeutic agent.
- 8. (Previously presented) A method of inducing apoptosis in a cancer cell, said method comprising introducing an antisense glucosylceramide synthase nucleic acid

sequence into said cancer cell, wherein said introduction induces apoptosis in said cells.

## 9. (Canceled)

- 10. (Currently amended) The method of claim 8, wherein said nucleic acid sequences are complementary to all or part of a sense strand for glucosylceramide synthase.
- 11. (Original) The method of claim 10, wherein said nucleic acid sequence is between about 15 to about 25 nucleotides in length.
- 12. (Original) The method of claim 8 wherein said cancer cell is selected from the group consisting of a breast cancer cell, prostate cancer cell, ovarian cancer cell, lymphoma cell, melanoma cell, sarcoma cell, leukemia cell, retinoblastoma cell, hepatoma cell, myeloma cell, glioma cell, mesothelioma cell or carcinoma cell.
- 13. (Original) The method of claim 8, further comprising the step of contacting said cell with at least one other agent.
- 14. (Original) The method of claim 13 wherein said agent is a chemosensitizer or chemotherapeutic agent.
- 15. (Previously presented) A formulation for reversing drug resistance in a cancer cell or inducing apoptosis in a cancer cell, comprising an antisense glucosylceramide synthase nucleic acid sequence and chemosensitizer or chemotherapeutic agent.

## 16. (Canceled)

- 17. (Previously presented) The formulation of claim 15 wherein said nucleic acid sequence is complementary to all or part of a sense strand for glucosylceramide synthase.
- 18. (Original) The formulation of claim 17, wherein said nucleic acid sequence is between about 15 to about 25 nucleotides in length.
- 19. (Original) A kit comprising the formulation of claim 15.
- 20. (Canceled)
- 21. (Previously presented) A method for reversing drug resistance in a cancer cell, said method comprising introducing a full length antisense glucosylceramide synthase nucleic acid sequence into said cell, wherein said introduction reverses drug resistance in said cell.
- 22. (Previously presented) A formulation for reversing drug resistance in a cancer cell or inducing apoptosis in a cancer cell, comprising a full length antisense glucosylceramide synthase nucleic acid sequence and chemosensitizer or chemotherapeutic agent.